Recent studies have demonstrated that the primary glutamine transporter, ASCT2, can promote tumor cell survival, growth and cell cycle progression in neuroblastoma, colorectal cancer, prostate cancer, clear-cell renal cell carcinoma and non-small cell lung cancer [43–47]. This evidence concerns the gene SLC1A5 and non-small cell lung carcinoma.